BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Larussa T, Suraci E, Marasco R, Imeneo M, Dumitrascu DL, Abenavoli L, Luzza F. Barriers and Facilitators in Conducting Clinical Trials in Inflammatory Bowel Disease: A Monocentric Italian Survey. Rev Recent Clin Trials 2020;15:137-44. [PMID: 32091346 DOI: 10.2174/1574887115666200224113520] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Schreiber S, Irving PM, Sharara AI, Martín-Arranz MD, Hébuterne X, Penchev P, Danese S, Anthopoulos P, Akhundova-Unadkat G, Baert F. Review article: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions. Aliment Pharmacol Ther 2022;55:658-69. [PMID: 35132657 DOI: 10.1111/apt.16781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Larussa T, Abenavoli L, Fabiano G, Mancuso MA, Polimeni N, Dumitrascu DL, Luzza F. Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed. Minerva Gastroenterol 2021;67. [DOI: 10.23736/s2724-5985.21.02907-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Snyder EF, Davis S, Aldrich K, Veerabagu M, Larussa T, Abenavoli L, Boccuto L. Crohn disease: Identification, diagnosis, and clinical management. Nurse Pract 2021;46:22-30. [PMID: 34808643 DOI: 10.1097/01.NPR.0000798212.61425.4f] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Rubin DT, Peyrin-biroulet L, Reinisch W, Tole S, Sullivan L, Park KT, Regueiro M. Inflammatory Bowel Disease Patients’ Perspectives of Clinical Trials: A Global Quantitative and Qualitative Analysis. Crohn's & Colitis 360 2021;3:otab079. [DOI: 10.1093/crocol/otab079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Foti PV, Travali M, Farina R, Palmucci S, Coronella M, Spatola C, Puzzo L, Garro R, Inserra G, Riguccio G, Zanoli L, Basile A. Can Conventional and Diffusion-Weighted MR Enterography Biomarkers Differentiate Inflammatory from Fibrotic Strictures in Crohn's Disease? Medicina (Kaunas) 2021;57:265. [PMID: 33803953 DOI: 10.3390/medicina57030265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Vent-schmidt J, Goldsmith LJ, Steiner TS. Patients’ Willingness and Perspectives Toward Chimeric Antigen Receptor T-Regulatory Cell Therapy for Inflammatory Bowel Diseases. Crohn's & Colitis 360 2020;2. [DOI: 10.1093/crocol/otaa085] [Reference Citation Analysis]
7 Larussa T, Flauti D, Abenavoli L, Boccuto L, Suraci E, Marasco R, Imeneo M, Luzza F. The Reality of Patient-Reported Outcomes of Health-Related Quality of Life in an Italian Cohort of Patients with Inflammatory Bowel Disease: Results from a Cross-Sectional Study. J Clin Med 2020;9:E2416. [PMID: 32731482 DOI: 10.3390/jcm9082416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Prasad SS, Keely S, Talley NJ, Kairuz T, Walker MM. Pharmacists' Confidence in Managing Patients with Inflammatory Bowel Disease. Pharmacy (Basel) 2020;8:E68. [PMID: 32316504 DOI: 10.3390/pharmacy8020068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]